{
    "title": "2.5 X reduced risk of cancer in 70 year-olds by a small amount of Vitamin D, Omega-3 and exercise \u2013 RCT",
    "slug": "25-x-reduced-risk-of-cancer-in-70-year-olds-by-a-small-amount-of-vitamin-d-omega-3-and-exercise-rct",
    "aliases": [
        "/25+X+reduced+risk+of+cancer+in+70+year-olds+by+a+small+amount+of+Vitamin+D+Omega-3+and+exercise+\u2013+RCT+April+2022",
        "/13516"
    ],
    "tiki_page_id": 13516,
    "date": "2022-04-25",
    "categories": [
        "Seniors",
        "Cancer - Colon",
        "Cancer - Prostate",
        "Intervention",
        "Vitamin D and Omega-3"
    ],
    "tags": [
        "Cancer - Colon",
        "Cancer - Prostate",
        "Intervention",
        "PCOS",
        "Seniors",
        "Vitamin D and Omega-3",
        "bone",
        "bone cancer",
        "breast cancer",
        "breathing",
        "cancer",
        "cancer in VDR",
        "colon cancer",
        "diabetes",
        "diabetes and vitamin d receptor",
        "falls fractures",
        "genetics",
        "health risk",
        "immunity",
        "leukemia",
        "life span",
        "lung cancer",
        "metabolic",
        "mortality",
        "omega 3",
        "omega 3 and pregnancy",
        "osteoporosis",
        "ovarian cancer",
        "pancreatic cancer",
        "pregnancy",
        "prostate cancer",
        "respiratory",
        "smoking",
        "vitamin d",
        "vitamin d blood test",
        "vitamin d receptor"
    ]
}


{{< toc >}} 

---

#### Combined Vitamin D, Omega-3 Fatty Acids, and a Simple Home Exercise Program May Reduce Cancer Risk Among Active Adults Aged 70 and Older: A Randomized Clinical Trial

Clinical Trial. Front. Aging 3:852643. [doi: 10.3389/fragi.2022.852643](https://doi.org/10.3389/fragi.2022.852643)

##### Overall Cancer Reduction vs each intervention

<img src="https://d1bk1kqxc0sym.cloudfront.net/attachments/png/d-o3-exercise---cancer.png" alt="image" width="600">

##### Types of Cancers vs each intervention

<img src="https://d1bk1kqxc0sym.cloudfront.net/attachments/jpeg/type-of-cancer.jpg" alt="image" width="600">

##### SHEP Exercise

<img src="https://d1bk1kqxc0sym.cloudfront.net/attachments/jpeg/shep-and-control-exercise.jpg" alt="image" width="800">

---

##### Data charted by [GRH](https://www.grassrootshealth.net/blog/3-keys-lower-cancer-risk-reduce-recurrence-improve-outcomes/?utm_source=newsletter-main&utm_medium=email&utm_campaign=Newsletters) (All 3 concurrently were very effective)

<img src="https://d1bk1kqxc0sym.cloudfront.net/attachments/jpeg/d-health-grh.jpg" alt="image" width="800">

---

Objective: The aim of this study was to test the individual and combined benefit of vitamin D, omega-3, and a simple home strength exercise program on the risk of any invasive cancer.

Design: The DO-HEALTH trial is a three-year, multicenter, 2x2x2 factorial design double-blind, randomized-controlled trial to test the individual and combined benefit of three public health interventions.

Setting: The trial was conducted between December 2012 and December 2017 in five European countries.

Participants: Generally healthy community-dwelling adults >70years were recruited.

Interventions: Supplemental  **2000 lU/day of vitamin D3, and/or 1 g/day of marine omega- 3s** , and/or a simple home strength exercise (SHEP) programme compared to placebo and control exercise.

Main outcome: In this pre-defined exploratory analysis, time-to-development of any verified invasive cancer was the primary outcome in an adjusted, intent-to-treat analysis.

Results: In total, 2,157 participants (mean age 74.9 years; 61.7% women; 40.7% with 25- OH vitamin D below 20/ml, 83% at least moderately physically active) were randomized. Over a median follow-up of 2.99 years, 81 invasive cancer cases were diagnosed and verified. For the three individual treatments, theadjusted hazard ratios (HRs, 95% CI, cases intervention versus control) were 0.76 (0.49-1.18; 36 vs. 45) for vitamin D3, 0.70 (0.44-1.09, 32 vs. 49) for omega-3s, and 0.74 (0.48-1.15, 35 vs. 46) for SHEP. For combinations of two treatments, adjusted HRs were 0.53 (0.28-1.00; 15 vs. 28 cases) for omega-3s plus vitamin D3; 0.56 (0.30-1.04; 11 vs. 21) for vitamin D3 plus SHEP; and 0.52 (0.28-0.97; 12 vs. 26 cases) for omega-3s plus SHEP. For all three treatments combined, the adjusted HR was 0.39 (0.18-0.85; 4 vs. 12 cases).

Conclusion: Supplementation with daily high-dose vitamin D3 plus omega-3s, combined with SHEP, showed cumulative reduction in the cancer risk in generally healthy and active and largely vitamin D-replete adults >70 years.

Clinical Trial Registration: ClinicalTrials.gov, Identifier: NCT01745263.

 **<i class="fas fa-file-pdf" style="margin-right: 0.3em;"></i><a href="https://d1bk1kqxc0sym.cloudfront.net/attachments/pdf/omega-3-exercise-to-reduce-cancer-risk-compresspdf.pdf">Study PDF </a>** 

 **<i class="fas fa-file-pdf" style="margin-right: 0.3em;"></i><a href="https://d1bk1kqxc0sym.cloudfront.net/attachments/pdf/exercise-supplement.pdf">SHEP Exercise PDF </a>** 

---

##### THE DO-HEALTH RESEARCH GROUP

The DO-HEALTH Research Group DO-HEALTH Consortium (in bold: Governing Board members; in bold and underlined: Chair; underlined: Team members). 

* Heike A Bischoff-Ferrari, DO-HEALTH Coordinator, Principal Investigator and Zurich Site Investigator, leads all endpoints analyses and co-leads the studies “DO-HEALTH health economic model,” “novel biomarkers of immunity,” “novel biomarkers of muscle and bone communication,” Andreas Egli and Sandrine Rival, University Hospital Zurich, University of Zurich and Waid and Triemli City Hospital, Zurich, Switzerland; 

* Bruno Vellas, Toulouse Site Investigator, contributes to the primary endpoint cognitive decline; Sophie Guyonnet, CHU Toulouse and University of Toulouse III, Toulouse, France; 

* René Rizzoli, Geneva Site Investigator, contributes to all bone- and muscle-related endpoints and explores the contribution of protein intake to the benefit of the interventions; Emmanuel Biver and Fanny Merminod RD, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland; 

* Reto W. Kressig, Basel Site Investigator, contributes to gait analyses and dual task assessments, and Stephanie Bridenbaugh, University Department of Geriatric Medicine FELIX PLATTER and University of Basel, Basel, Switzerland; Norbert Suhm, Department. of Traumatology, University Hospital Basel, contributes to fracture healing study DO-HEALTH; 

* José A. P. Da Silva, Coimbra Site Investigator, explores the treatment effects on vertebral fractures, and musculoskeletal pain and function, Centro Hospitalar e Universitario de Coimbra, and Faculty of Medicine, University of Coimbra, Coimbra, Portugal; 

   * Catia C. M. Duarte, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal; Ana Filipa Pinto R. N., Faculty of Medicine, University of Coimbra, Coimbra, Portugal; 

* DieterFelsenberg, Berlin SiteInvestigator, performed the central DO-HEALTH DEXA quality control and evaluation of DEXA measurements; 

   * Hendrikje Börst Dipl.Wiss-org, and Gabriele Armbrecht, Charité—Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 

* Michael Blauth, Innsbruck Site Investigator, explores the functionality after fracture; Anna Spicher, Medical University of Innsbruck, Innsbruck, Austria; 

* David T. Felson, co-leads “DO-HEALTH osteoarthritis study,” Manchester Academic Health Science Center, Manchester, United Kingdom and Boston University School of Medicine, Boston, MA, United States; 

* John A. Kanis, leads the study “contribution of fall risk to absolute fracture risk within the FRAX model,” University of Sheffield Medical School, Sheffield, United Kingdom and Australian Catholic University, Melbourne, Victoria, Australia; 

   * Eugene V. Mccloskey, co-leads the study “contribution of fall risk to absolute fracture risk within the FRAX model,” University of Sheffield, Sheffield, United Kingdom; Helena Johansson, University of Sheffield Medical School,	Sheffield, United Kingdom and Catholic University of Australia, Melbourne, Victoria, Australia; 

* Bernhard Watzl, co-leads the study “novel biomarkers of immunity,” Manuel Rodriguez Gomez, Max Rubner-Institut, Karlsruhe, Germany; 

* Lorenz C. Hofbauer, co-leads the study “novel biomarkers of muscle and bone communication,” Elena Tsourdi and Martina Rauner, Dresden University Medical Center and Center for Regenerative Therapies Dresden, Dresden, Germany; 

* Uwe Siebert, co-leads the study “DO-HEALTH health economic model,” UMIT—University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria and Harvard T. H. Chan School of Public Health, Boston, MA, United States and Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States; 

* John A. Kanis, leads DO-HEALTH impact and communication of osteoporosis-related findings on a broad level, and Philippe Halbout PhD, IOF; 

* Stephen M. Ferrari, leads DO-HEALTH software development (electronic data capture system and interactive practical software for seniors and healthcare professionals that teaches main findings of DO-HEALTH), Ferrari Data Solutions, Feldmeilen, Switzerland; 

* Benno Gut, leads DO- HEALTH visual communication (SHEP avatar) and DO- HEALTH corporate design structures (logo, website software, and communication tools), gut pictures, Horgen, Switzerland; 

* Marième Ba, was the DO-HEALTH independent clinical monitoring partner, Pharmalys, Borehamwood, United Kingdom; 

* Jonas Wittwer Schegg, industrial partner representative bringing expertise and facilities in plasma analytics for 25-hydroxyvitamin D and omega-3 fatty acids and providing the study medication (vitamin D, omega-3 fatty acids); 

   * Stéphane Etheve, DSM Nutritional Products, Kaiseraugst, Switzerland; Manfred Eggersdorfer, University Medical Center Groningen, Gronigen, Netherlands; 

* Carla Sofia Delannoy, industrial partner representative providing financial support to DO- HEALTH central coordination, Nestlé Health Science, Lausanne, Switzerland; 

* Monika Reuschling, industrial partner representative providing assays for the large DO- HEALTH biomarker study to define reference ranges of common biomarkers in adults aged 70+, Roche diagnostiscs, Rotkreuz, Switzerland.

 **DO-HEALTH Scientific Advisory Board members and collaborators on specific outcomes** 

* Endel J. Orav, Harvard T. H. Chan School of Public Health; Boston, MA, United States; 

* Walter C. Willett, Harvard T. H. Chan School of Public Health, Boston, MA, United States; 

* JoAnn E. Manson, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States; 

* Bess Dawson-Hughes,	Tufts	University, Boston, MA, United States; 

* Hannes B. Staehelin, University of Basel, Basel, Switzerland; 

* Paul W. Walter, University of Basel, Basel, Switzerland; 

* Walter Dick, University of Basel, Basel, Switzerland; 

* Michael Fried, University of Zurich, Zurich, Switzerland; 

* Arnold von Eckardstein, University of Zurich, Zurich, Switzerland; 

* Robert Theiler, University Hospital Zurich and University of Zurich, Zurich, Switzerland; 

* Hans-Peter Simmen, University of Zurich, Zurich, Switzerland; 

* Wolfgang Langhans, ETH Zurich, Zurich, Switzerland; 

* Annelies Zinkernagel, University Hospital of Zurich, Zurich, Switzerland; 

* Nicolas Mueller, University Hospital of Zurich, Zurich, Switzerland; 

* Oliver Distler, University Hospital of Zurich, Zurich, Switzerland; 

* Klaus Graetz, University Hospital of Zurich, Zurich, Switzerland; 

* Ina Nitschke, University Hospital of Zurich, Zurich, Switzerland; 

* Thomas Dietrich, University of Birmingham, United Kingdom; 

* Walter Baer, University of Zurich, Zurich, Switzerland; 

* Klara Landau, University Hospital of Zurich, Zurich, Switzerland; 

* Frank Ruschitzka, University Hospital of Zurich, Zurich, Switzerland; 

* Markus Manz, University Hospital of Zurich, Zurich, Switzerland; 

* Peter Burckhardt, University of Lausanne, Lausanne, Switzerland.

##### REFERENCES (many of which are DO-HEALTH)

* Altman, D. G., and Andersen, P. K. (1999). Calculating the Number Needed to Treat for Trials where the Outcome Is Time to an Event. BMJ 319,1492-1495. doi:10.1136/bmj.319.7223.1492

* Bischoff-Ferrari, H. A., Dawson-Hughes, B., Orav, E. J., Staehelin, H. B., Meyer, O. W., Theiler, R., et al. (2016). Monthly High-Dose Vitamin D Treatment for the Prevention of Functional Decline. JAMA Intern. Med. 176, 175-183. doi:10. 1001/jamainternmed. 2015.7148

* Bischoff-Ferrari, H. A., De Godoi Rezende Costa Molino, C., Rival, S., Vellas, B., Rizzoli, R., Kressig, R. W., et al. (2021). Do-HEALTH: Vitamin D3 - Omega-3 - Home Exercise - Healthy Aging and Longevity Trial - Design of a Multinational Clinical Trial on Healthy Aging Among European Seniors. Contemp. Clin. Trials 100, 106124. doi:10.1016/j.cct.2020.106124 

* Bischoff-Ferrari, H. A. Vellas, B. , Rizzoli, R. , Kressig, R. W. , Da Silva, J. A. P. Blauth, M. , et al. (2020). Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults. JAMA 324, 1855-1868. doi:10.1001/jama.2020.16909 

* Bolland, M. J., Grey, A., and Avenell, A. (2018). Effects of Vitamin D Supplementation on Musculoskeletal Health: a Systematic Review, MetaAnalysis, and Trial Sequential Analysis. Lancet Diabetes Endocrinol. 6, 847-858. doi:10.1016/s2213-8587(18)30265-1 

* Calviello, G., Serini, S., and Piccioni, E. (2007). n-3 Polyunsaturated Fatty Acids and the Prevention of Colorectal Cancer: Molecular Mechanisms Involved. Cmc 14, 3059-3069. doi:10.2174/092986707782793934 

* Campbell, M. J., Elstner, E., Holden, S., Uskokovic, M., and Koeffler, H. P. (1997). Inhibition of Proliferation of Prostate Cancer Cells by a 19-Nor-Hexafluoride Vitamin D3 Analogue Involves the Induction of P21waf1, P27kip1 and E-Cadherin. J. Mol. Endocrinol. 19, 15-27. doi:10.1677/jme.0.0190015 

* Chandler, P. D., Chen, W. Y., Ajala, O. N., Hazra, A., Cook, N., Bubes, V., et al. (2020). Effect of Vitamin D3 Supplements on Development of Advanced Cancer. JAMA Netw. Open 3, e2025850. doi:10.1001/jamanetworkopen.2020. 25850

* Collaborative Group on Hormonal Factors in Breast, C. (2019). Type and Timing of Menopausal Hormone Therapy and Breast Cancer Risk: Individual Participant Meta-Analysis of the Worldwide Epidemiological Evidence. Lancet 394, 1159-1168. doi:10.1016/S0140-6736(19)31709-X 

* Cormie, P., Zopf, E. M., Zhang, X., and Schmitz, K. H. (2017). The Impact of Exercise on Cancer Mortality, Recurrence, and Treatment-Related Adverse Effects. Epidemiol. Rev. 39, 71-92. doi:10.1093/epirev/mxx007 

* Di Leo, G., and Sardanelli, F. (2020). Statistical Significance: P Value, 0.05 Threshold, and Applications to Radiomics-Reasons for a Conservative Approach. Eur. Radiol. Exp. 4, 18. doi:10.1186/s41747-020-0145-y 

* Diaz, G. D., Paraskeva, C., Thomas, M. G., Binderup, L., and Hague, A. (2000). Apoptosis Is Induced by the Active Metabolite of Vitamin D3 and its Analogue EB1089 in Colorectal Adenoma and Carcinoma Cells: Possible Implications for Prevention and Therapy. Cancer Res. 60, 2304-2312.

* Dierge, E., Debock, E., Guilbaud, C., Corbet, C., Mignolet, E., Mignard, L., et al. (2021). Peroxidation ofN-3 and N-6 Polyunsaturated Fatty Acids in the Acidic Tumor Environment Leads to Ferroptosis-Mediated Anticancer Effects. Cel Metab. 33, 1701-1715. e1705. doi:10.1016/j.cmet.2021.05.016 

* Dragnev, K. H., Stover, D., Dmitrovsky, E., and American College of Chest, P. (2003). Lung Cancer Prevention*. Chest 123, 60S-71S. doi:10.1378/chest.123. 1_suppl.60s

* Emmons, K. M., and Colditz, G. A. (2017). Realizing the Potential of Cancer Prevention - the Role ofImplementation Science. N. Engl. J. Med. 376,986-990. doi:10.1056/nejmsb1609101

* Fay, M. P., Freedman, L. S., Clifford, C. K., and Midthune, D. N. (1997). Effect of Different Types and Amounts ofFat on the Development ofMammary Tumors in Rodents: a Review. Cancer Res. 57, 3979-3988.

* Gaschott, T., and Stein, J. (2003). Short-Chain Fatty Acids and Colon Cancer Cells: The Vitamin D Receptor-Butyrate Connection. Recent Results CancerRes. 164, 247-257. doi:10.1007/978-3-642-55580-0_18 

* Ginde, A. A., Blatchford, P., Breese, K., Zarrabi, L., Linnebur, S. A., Wallace, J. I., et al. (2017). High-Dose Monthly Vitamin D for Prevention of Acute Respiratory Infection in Older Long-Term Care Residents: A Randomized Clinical Trial. J. Am. Geriatr. Soc. 65, 496-503. doi:10. 1111/jgs. 14679

* Haidari, F., Abiri, B., Iravani, M., Ahmadi-Angali, K., and Vafa, M. (2020). Effects of Vitamin D and Omega-3 Fatty Acids Co-supplementation on Inflammatory Factors and Tumor Marker CEA in Colorectal Cancer Patients Undergoing Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Nutr. Cancer 72, 948-958. doi:10. 1080/01635581.2019.1659380

* Han, J., Guo, X.,Yu,X., Liu, S., Cui, X., Zhang, B.,etal. (2019). 25-Hydroxyvitamin D and Total Cancer Incidence and Mortality: A Meta-Analysis of Prospective Cohort Studies. Nutrients 11, 1. doi:10.3390/nu11102295 

* Hanson, S., Thorpe, G., Thorpe, G., Winstanley, L., Abdelhamid, A. S., and Hooper, L. (2020). Omega-3, omega-6 and Total Dietary Polyunsaturated Fat on Cancer Incidence: Systematic Review and Meta-Analysis of Randomised Trials. Br. J. Cancer 122, 1260-1270. doi:10.1038/s41416-020-0761-6 

* Haykal, T., Samji, V., Zayed, Y., Gakhal, I., Dhillon, H., Kheiri, B., et al. (2019). The Role ofVitamin D Supplementation for Primary Prevention of Cancer: Meta-Analysis of Randomized Controlled Trials. J. Community Hosp. Intern. Med. Perspect. 9, 480-488. doi:10.1080/20009666.2019. 1701839

* Hong, B. S., and Lee, K. P. (2020). A Systematic Review of the Biological Mechanisms Linking Physical Activity and Breast Cancer. Phys. Act Nutr. 24, 25-31. doi:10.20463/pan.2020.0018

* James, S. Y., Mackay, A. G., and Colston, K. W. (1996). Effects of 1,25 Dihydroxyvitamin D3 and its Analogues on Induction of Apoptosis in Breast Cancer Cells. J. Steroid Biochem. Mol. Biol. 58, 395-401. doi:10.1016/ 0960-0760(96)00048-9

* Jamilian, M., Samimi, M., Mirhosseini, N., Afshar Ebrahimi, F., Aghadavod, E., Talaee, R., et al. (2018). The Influences ofVitamin D and omega-3 Co-supplementation on Clinical, Metabolic and Genetic Parameters in Women with Polycystic Ovary Syndrome. J. Affective Disord. 238, 32-38. doi:10.1016/j.jad.2018.05.027 

* Jiang, F., Bao, J., Li, P., Nicosia, S. V., and Bai, W. (2004). Induction of Ovarian Cancer Cell Apoptosis by 1,25-dihydroxyvitamin D3 through the Down-Regulation of Telomerase. J. Biol. Chem. 279, 53213-53221. doi:10.1074/jbc.m410395200 

* Jolliffe, D. A., Camargo, C. A., Sluyter, J. D., Aglipay, M., Aloia, J. F., Ganmaa, D., et al. (2020). Vitamin D Supplementation to Prevent Acute Respiratory Infections: Systematic Review and Meta-Analysis of Aggregate Data from Randomised Controlled Trials. medRxiv. doi:10.1101/2020.07.14.20152728 

* Kawa, S., Yoshizawa, K., Tokoo, M., Imai, H., Oguchi, H., Kiyosawa, K., et al. (1996). Inhibitory Effect of 220-Oxa-1,25-Dihydroxyvitamin D3 on the Proliferation of Pancreatic Cancer Cell Lines. Gastroenterology 110, 1605-1613. doi:10.1053/gast.1996.v110.pm8613068 

* Keum, N., Lee, D. H., Greenwood, D. C., Manson, J. E., and Giovannucci, E. (2019). Vitamin D Supplementation and Total Cancer Incidence and Mortality: a Meta-Analysis of Randomized Controlled Trials. Ann. Oncol. 30, 733-743. doi:10.1093/annonc/mdz059

* Kim, H., and Giovannucci, E. (2020). Vitamin D Status and Cancer Incidence, Survival, and Mortality. Adv. Exp. Med. Biol. 1268, 39-52. doi:10.1007/978-3- 030-46227-7_3

* Koga, M., Eisman, J. A., and Sutherland, R. L. (1988). Regulation of Epidermal Growth Factor Receptor Levels by 1,25-dihydroxyvitamin D3 in Human Breast Cancer Cells. Cancer Res. 48, 2734-2739.

* Kumagai, T., Shih, L.-Y., Hughes, S. V., Desmond, J. C., O’kelly, J., Hewison, M., et al. (2005). 19-Nor-1,25(OH)2D2(a Novel, Noncalcemic Vitamin D Analogue), Combined with Arsenic Trioxide, Has Potent Antitumor Activity against Myeloid Leukemia. Cancer Res. 65, 2488-2497. doi:10.1158/ 0008-5472.can-04-2800

* Laconi, E., Marongiu, F., and Degregori, J. (2020). Cancer as a Disease of Old Age: Changing Mutational and Microenvironmental Landscapes. Br. J. Cancer 122, 943-952. doi:10.1038/s41416-019-0721-1 

* Larsson, S. C., Kumlin, M., Ingelman-Sundberg, M., and Wolk, A. (2004). DietaryLong- Chain N-3 Fatty Acids for the Prevention of Cancer: a Review of Potential Mechanisms. Am. J. Clin. Nutr. 79, 935-945. doi:10.1093/ajcn/79.6.935 

* Li, P., Li, C., Zhao, X., Zhang, X., Nicosia, S. V., and Bai, W. (2004). p27Kip1 Stabilization and G1 Arrest by 1,25-Dihydroxyvitamin D3 in Ovarian Cancer Cells Mediated through Down-Regulation of Cyclin E/Cyclin-dependent Kinase 2 and Skp1-Cullin-F-Box Protein/Skp2 Ubiquitin Ligase. J. Biol. Chem. 279, 25260-25267. doi:10.1074/jbc.m311052200 

* Lopez-Otin, C., Blasco, M. A., Partridge, L., Serrano, M., and Kroemer, G. (2013). The Hallmarks ofAging. Cell 153, 1194-1217. doi:10.1016/j.cell.2013.05.039 

* MacLean, C. H., Newberry, S. J., Mojica, W. A., Khanna, P., Issa, A. M., Suttorp, M. J., et al. (2006). Effects of Omega-3 Fatty Acids on Cancer Risk. JAMA 295, 403-415. doi:10.1001/jama.295.4.403

* Manson, J. E., Cook, N. R., Lee, I.-M., Christen, W., Bassuk, S. S., Mora, S., et al. (2019a). Marine N-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N. Engl. J. Med. 380, 23-32. doi:10.1056/nejmoa1811403 

* Manson, J. E., Cook, N. R., Lee, I.-M., Christen, W., Bassuk, S. S., Mora, S., et al. (2019b). Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N. Engl. J. Med. 380, 33-44. doi:10.1056/nejmoa1809944 

* McTiernan, A., Schwartz, R. S., Potter, J., and Bowen, D. (1999). Exercise Clinical Trials in Cancer Prevention Research: a Call to Action. Cancer Epidemiol. Biomarkers Prev. 8, 201-207.

* McTiernan, A. (2008). Mechanisms Linking Physical Activity with Cancer. Nat.Rev. Cancer 8, 205-211. doi:10.1038/nrc2325 Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., et al. (2017). Combination Therapy in Combating Cancer. Oncotarget 8, 38022-38043. doi:10.18632/oncotarget.16723 

* Moreno, J., Krishnan, A. V., Swami, S., Nonn, L., Peehl, D. M., and Feldman, D. (2005). Regulation of Prostaglandin Metabolism by Calcitriol Attenuates Growth Stimulation in Prostate Cancer Cells. Cancer Res. 65, 7917-7925. doi:10.1158/0008-5472.can-05-1435

* Reid, A., De Klerk, N. H., Ambrosini, G. L., Berry, G., and Musk, A. W. (2006). The Risk of Lung Cancer with Increasing Time since Ceasing Exposure to Asbestos and Quitting Smoking. Occup. Environ. Med. 63, 509-512. doi:10.1136/oem.2005.025379 

* Rezende, L. F. M. d., Sa, T. H. d., Markozannes, G., Rey-Lopez, J. P., Lee, I.-M., Tsilidis, K. K., et al. (2018). Physical Activity and Cancer: an Umbrella Review of the Literature Including 22 Major Anatomical Sites and 770 000 Cancer Cases. Br. J. Sports Med. 52, 826-833. doi:10.1136/bjsports-2017-098391 

* Sabia, S., Singh-Manoux, A., Hagger-Johnson, G., Cambois, E., Brunner, E. J., and Kivimaki, M. (2012). Influence of Individual and Combined Healthy Behaviours on Successful Aging. CMAJ 184, 1985-1992. doi:10.1503/cmaj. 121080

* Sanders, K. M., Stuart, A. L., Williamson, E. J., Simpson, J. A., Kotowicz, M. A., Young, D., et al. (2010). Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women. JAMA 303, 1815-1822. doi:10.1001/jama.2010.594 

* Smith, H., Anderson, F., Raphael, H., Maslin, P., Crozier, S., and Cooper, C. (2007). Effect of Annual Intramuscular Vitamin D on Fracture Risk in Elderly Men and Women a Population-Based, Randomized, Double-Blind, Placebo-Controlled Trial. Rheumatology 46, 1852-1857. doi:10.1093/rheumatology/kem240 

* Snaebjornsson, M. T., Janaki-Raman, S., and Schulze, A. (2020). Greasing the Wheels of the Cancer Machine: The Role of Lipid Metabolism in Cancer. Cel Metab. 31, 62-76. doi:10.1016/j.cmet.2019.11.010 

* Sundaram, S., Chaudhry, M., Reardon, D., Gupta, M., and Gewirtz, D. A. (2000). The Vitamin D3 Analog EB 1089 Enhances the Antiproliferative and Apoptotic Effects of Adriamycin in MCF-7 Breast Tumor Cells. Breast Cancer Res. Treat. 63, 1-10. doi:10.1023/a:1006420708806

* Virtanen, J. K., Nurmi, T., Aro, A., Bertone-Johnson, E. R., Hyppönen, E., Kröger, H., et al. (2022). Vitamin D Supplementation and Prevention of Cardiovascular Disease and Cancer in the Finnish Vitamin D Trial—A Randomized Controlled Trial. Am. J. Clin. Nutr. 2022, nqab419. doi:10.1093/ajcn/nqab419 

* Wang, Q., and Zhou, W. (2020). Roles and Molecular Mechanisms of Physical Exercise in Cancer Prevention and Treatment. J. Sport Health Sci. 10 (2), 201-210. doi:10.1016/j.jshs.2020.07.008

* White, M. C., Holman, D. M., Boehm, J. E., Peipins, L. A., Grossman, M., and Jane Henley, S. (2014). Age and Cancer Risk. Am. J. Prev. Med. 46, S7-S15. doi:10. 1016/j.amepre.2013.10.029

* Yanagisawa, J., Yanagi, Y., Masuhiro, Y., Suzawa, M., Watanabe, M., Kashiwagi, K., et al. (1999). Convergence of Transforming Growth Factor-ß and Vitamin D Signaling Pathways on SMAD Transcriptional Coactivators. Science 283, 1317-1321. doi:10.1126/science.283.5406.1317

---

#### Vitamin D is the 3rd best way to improve your health (but the most cost-effective)

<img src="/attachments/d3.mock.jpg" alt="image" width="550">